Physician profile
Troy M Lamar
NPI 1376629030
$10,729.66
in general payments reported to CMS, 2019-2025
14 companies · $194 in 2025
The $194 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $171 · 2021: $241 · 2022: $8,798 · 2023: $99.90 · 2024: $947 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $740 · Honoraria: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.17 |
| Honoraria | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,567.49 | 2022 | |
| Intra-Sana Laboratories | $644.76 | 2024-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Ethicon US, LLC | $475.10 | 2019-2025 | Echelon Flex, Echelon; Endopath, Echelon Endopath |
| Medtronic, INC. | $360.13 | 2021-2025 | Venaseal |
| Boston Scientific Corporation | $233.51 | 2022-2025 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd |
| Covidien LP | $147.12 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.18 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $87.67 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.65 | 2020-2021 | |
| Amgen INC. | $22.63 | 2020 | |
| Atricure, INC. | $21.97 | 2023 | |
| Karl Storz Endoscopy-America | $11.45 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$49,991.04 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Lamar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.